Hepion Pharmaceuticals (FRA:336) COGS-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Hepion Pharmaceuticals COGS-to-Revenue?

Hepion Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2024 was €0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was €0.00 Mil.

Hepion Pharmaceuticals's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Hepion Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2024 was N/A%.

Hepion Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Hepion Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals COGS-to-Revenue Chart

Hepion Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

Hepion Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Hepion Pharmaceuticals COGS-to-Revenue Calculation

Hepion Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Hepion Pharmaceuticals's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Hepion Pharmaceuticals (FRA:336) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Hepion Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Hepion Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Hepion Pharmaceuticals (FRA:336) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (FRA:336) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

HEPA:USA

Address

399 Thornall Street, First Floor, Edison, NJ, USA, 08837

Website

https://www.hepionpharma.com

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Hepion Pharmaceuticals (FRA:336) Headlines

No Headlines